Vical, AnGes deal

VICL granted AnGes exclusive marketing rights to Allovectin-7 for recurrent metastatic melanoma in Japan, China and certain other Asian countries. VICL will receive $11.8 million in cash and $10.9 million in two equity investments from AnGes to fund an upcoming Phase III trial of the gene encoding HLA-B7 mismatched transplantation antigen complexed with lipids. VICL also is eligible for up to $77.5 million in sales-based milestones, plus royalties in countries where AnGes has rights. AnGes is eligible for royalties in VICL's territories. ...